F025 The Changing Landscape of Early-stage Melanoma Management
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
There have been many recent advances in our understanding of potential therapeutic and management options for patients with early-stage melanoma (ie, melanoma confined only to the skin). This session will discuss how to incorporate this information into practice, as well as discuss relevant clinical trials. Topics include a review of relevant findings in recent literature, an exploration of the phenomenon of melanoma overdiagnosis, how to best identify patients who would benefit from germline genetic testing, the use of histopathologic stains and other tools for melanoma diagnosis, and the role of adjuvant and neoadjuvant therapies for early-stage melanoma patients.
LEARNING OBJECTIVES
Describe some of the recent melanoma literature and discuss the phenomenon of melanoma overdiagnosis
Discuss how to identify patients who would benefit from germline genetic testing for mutations in CDKN2A, BAP-1, and other relevant genes, and describe the appropriate role of histopathologic stains and other pathologic tools when making melanoma diagnoses
Describe adjuvant and neoadjuvant therapies being explored for patients with thicker melanomas
SCHEDULE
2:00 PM
Introduction
Michael E. Ming, MD, FAAD
2:05 PM
What lessons can we take from recent melanoma literature?
Michael E. Ming, MD, FAAD
2:25 PM
How concerned should we be about melanoma overdiagnosis?
Rebecca I Hartman, MD, MPH, FAAD
2:45 PM
How can we best identify which patients should be referred for germline genetic testing?
Kelly C Nelson, MD, FAAD
3:05 PM
When are histopathologic stains and other pathologic tools helpful (and not helpful) when making melanoma diagnoses?
Emily Y. Chu, MD, PhD, FAAD
3:25 PM
My patient has a thick melanoma — now what?: the role of adjuvant and neoadjuvant therapy
John Miura, MD
3:45 PM
Q & A
SPEAKERS
Emily Y. Chu, MD, PhD, FAAD
Rebecca I Hartman, MD, MPH, FAAD
Michael E. Ming, MD, FAAD
John Miura, MD
Kelly C Nelson, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Emily Y. Chu, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Rebecca I Hartman, MD, MPH, FAAD
Almirall – Consultant (1099 relationship)(Fees); Evereden – Advisory Board(Stock), Consultant(Fees); Med Learning Group – Speaker/Faculty Education(Fees); MJH Life Sciences – Consultant (1099 relationship)(Fees); Oasis Pharmaceuticals – Data Safety Monitoring Board(Fees); Zura Bio – Data Safety Monitoring Board(Fees);
Michael E. Ming, MD, FAAD
No financial relationships exist with ineligible companies.
John Miura, MD
No financial relationships exist with ineligible companies.
Kelly C Nelson, MD, FAAD
No financial relationships exist with ineligible companies.